Abstract
experience of the PolyHeme trial. “We have a conundrum in this country,” said Gould, Chief Executive Officer of Northfield. “It’s the balance between the need to respect patients’ rights and the need to conduct rigorous scientific studies in emergency life-threatening situations. Those are the opportunities for some of the greatest advances in care, and yet it is virtually impossible to do them with the traditional approach to informed consent.”
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
